The board and staff of Melanoma and Skin Cancer Trials wish Elizabeth ‘Libby’ Paton all the best for her departure and in all future endeavours.
Over her 12 years as Chief Executive Officer of Melanoma and Skin Cancer Trials (formerly known as Australian and New Zealand Melanoma Trials Group, ANZMTG), Libby has worked tirelessly to grow the organisation into one of Australia’s most respected clinical trial groups.
Her collaborative approach and determination to bring together and empower the best researchers have enabled impactful and influential clinical trials that otherwise may not have been possible.
Melanoma and Skin Cancer Trials would like to express our sincerest gratitude to Libby for all she has done, both for our organisation and for melanoma and skin cancer research in general.
Statement from Professor Mark Shackleton, Chairman, Melanoma and Skin Cancer Trials
“One cannot overstate Libby’s contribution to our national melanoma and skin cancer trials group, first in her operational roles with ANZMTG from 2008, then in leading the group during a critical period of change across 2014-16.
Most recently, she has been instrumental in overseeing the transformation from ANZMTG to the incorporated, not-for-profit, independent entity ‘Melanoma and Skin Cancer Trials’, and in securing an outstanding research environment at Monash University for our operations.
Libby’s drive, energy, and commitment have been inspirational. She leaves our organisation well placed to address the key research questions of the coming era of innovation and advancement in melanoma and skin cancer treatment, with enormous benefits for patients and families affected by these diseases.”